1-benzyl-5-bromo-2-phenyl-1H-benzo[d]imidazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 1-benzyl-5-bromo-2-phenyl-1H-benzo[d]imidazole
• 英文别名: 1-benzyl-5-bromo-2-phenyl-benzo[d]imidazole；1-benzyl-5-bromo-2-phenyl-1H-benzimidazole；1-benzyl-5-bromo-2-phenylbenzimidazole
• 化学式: C₂₀H₁₅BrN₂
• 分子量: 363.256
• InChiKey: UCRSTGRDIQTGFS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  4-溴-1-氟-2-硝基苯 在 碘苯 、 铁粉 、 potassium carbonate 、 氯化铵 、 间氯过氧苯甲酸 作用下， 以 乙醇 、 二氯甲烷 、 水 、 二甲基亚砜 为溶剂， 反应 28.0h， 生成 1-benzyl-5-bromo-2-phenyl-1H-benzo[d]imidazole
  参考文献：
  名称：

  An intramolecular C(sp³)–H imination using PhI–mCPBA

  摘要：

  开发可持续方法来活化较不活泼的无向C(sp³)–H键在有机合成中具有挑战性但是受欢迎。本手稿展示了使用PhI (10 mol%)–mCPBA作为有机催化剂进行脱氢C–H亚胺化反应，实现对酸性C(sp³)–H基团的选择性活化。

  DOI：

  10.1039/c8cc09100e

文献信息

• Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors
  申请人：Buck A. Elizabeth

  公开号：US20070280928A1

  公开（公告）日：2007-12-06

  The present invention provides a method for treating NSCL, pancreatic, colon or breast cancer tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of a combination of an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors, wherein the agent is an mTOR inhibitor, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The present invention also provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors, wherein said agent is an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases. The present invention also provides a pharmaceutical composition comprising an EGFR kinase inhibitor and an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases, in a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing the methods of this invention is the compound erlotinib HCl (also known as TARCEVA®).

  本发明提供了一种治疗患者体内NSCL、胰腺、结肠或乳腺癌肿瘤或肿瘤转移的方法，包括向患者同时或顺序给予治疗有效量的EGFR激酶抑制剂和一种使肿瘤细胞对EGFR激酶抑制剂产生敏感性的药物的组合，其中该药物是mTOR抑制剂，可以附加其他药物或治疗，如其他抗癌药物或放射治疗。本发明还提供了一种治疗患者体内肿瘤或肿瘤转移的方法，包括向患者同时或顺序给予治疗有效量的EGFR激酶抑制剂和一种使肿瘤细胞对EGFR激酶抑制剂产生敏感性的药物的组合，其中该药物是一种能够结合并直接抑制mTORC1和mTORC2激酶的mTOR抑制剂。本发明还提供了一种制药组合物，包括一种能够结合并直接抑制mTORC1和mTORC2激酶的EGFR激酶抑制剂和mTOR抑制剂，以及一种药用载体。本发明中可用于实施该方法的EGFR激酶抑制剂的首选示例是化合物厄洛替尼盐酸盐（也称为TARCEVA®）。
• Fused bicyclic mTOR inhibitors
  申请人：Chen Xin

  公开号：US20070112005A1

  公开（公告）日：2007-05-17

  Compounds represented by Formula (I) or a pharmaceutically acceptable salt thereof, are inhibitors of mTOR and useful in the treatment of cancer.

  由化学式(I)代表的化合物或其药用可接受的盐，是mTOR的抑制剂，可用于癌症的治疗。
• An intramolecular C(sp³)–H imination using PhI–<i>m</i>CPBA
  作者：Anima Bose、Saikat Maiti、Sudip Sau、Prasenjit Mal

  DOI：10.1039/c8cc09100e

  日期：——

  Development of sustainable methods for the activation of less reactive undirected C(sp³)–H bonds is challenging but desired in organic synthesis. The present manuscript demonstrates selective activation of acidic C(sp³)–H groups for a dehydrogenative C–H imination reaction by 4H elimination using PhI (10 mol%)–mCPBA as an organocatalyst.

  开发可持续方法来活化较不活泼的无向C(sp³)–H键在有机合成中具有挑战性但是受欢迎。本手稿展示了使用PhI (10 mol%)–mCPBA作为有机催化剂进行脱氢C–H亚胺化反应，实现对酸性C(sp³)–H基团的选择性活化。
• One-pot strategy of copper-catalyzed synthesis of 1,2-disubstituted benzimidazoles
  作者：Caixia Xie、Xushuang Han、Jian Gong、Danyang Li、Chen Ma

  DOI：10.1039/c7ob00945c

  日期：——

  A simple, one-pot and copper-catalyzed coupling reaction for the construction of 1,2-disubstituted benzimidazole derivatives is described. Low-cost copper salt and weak base K3PO4 were utlized in this reaction. A variety of 1,2-disubstituted benzimidazoles were obtained in moderate to excellent yields.

  描述了一种简单的，一锅法和铜催化的偶联反应，用于构建1,2-二取代的苯并咪唑衍生物。在该反应中使用了廉价的铜盐和弱碱K3PO4。以中等至优异的产率获得了各种1,2-二取代的苯并咪唑。
• 헤테로아릴 치환기를 갖는 나프틸기를 포함하는 안트라센 유도체 및 이를 포함하는 유기 발광 소자
  申请人：SFC CO., LTD. 에스에프씨 주식회사(120060087061) Corp. No ▼ 135511-0105889BRN ▼134-81-54429

  公开号：KR102002025B1

  公开（公告）日：2019-07-19

  본 발명은 하기 [화학식 A]로 표시되는 안트라센 유도체 및 이를 포함하는 유기 발광 소자에 관한 것으로 치환기 X내지 X, Y및 Z 은 발명의 상세한 설명에 기재된 바에 의하여 정의된 바와 동일하다. [화학식 A]

  本发明涉及一种以化学式A表示的蒽衍生物及包含该蒽衍生物的有机发光器件，其中取代基X至X、Y和Z如在本发明的详细描述中所定义的那样。【化学式A】